Immunotherapy in cancer: current status and future prospects. 1979

G Vosika

UI MeSH Term Description Entries
D007167 Immunotherapy Manipulation of the host's immune system in treatment of disease. It includes both active and passive immunization as well as immunosuppressive therapy to prevent graft rejection. Immunotherapies
D009369 Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms. Benign Neoplasm,Cancer,Malignant Neoplasm,Tumor,Tumors,Benign Neoplasms,Malignancy,Malignant Neoplasms,Neoplasia,Neoplasm,Neoplasms, Benign,Cancers,Malignancies,Neoplasias,Neoplasm, Benign,Neoplasm, Malignant,Neoplasms, Malignant
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D001500 BCG Vaccine An active immunizing agent and a viable avirulent attenuated strain of MYCOBACTERIUM BOVIS, which confers immunity to mycobacterial infections. It is used also in immunotherapy of neoplasms due to its stimulation of antibodies and non-specific immunity. Bacillus Calmette Guerin Vaccine,Calmette Guerin Bacillus Vaccine,Calmette's Vaccine,Calmette Vaccine,Calmettes Vaccine,Vaccine, BCG,Vaccine, Calmette's

Related Publications

G Vosika
October 1996, Immunology and cell biology,
G Vosika
January 2023, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie,
G Vosika
May 2014, American journal of respiratory cell and molecular biology,
G Vosika
January 2021, [Rinsho ketsueki] The Japanese journal of clinical hematology,
G Vosika
February 1993, The Journal of dermatology,
G Vosika
April 2016, The Journal of allergy and clinical immunology,
Copied contents to your clipboard!